Tuesday Jun 30 | MediLexicon
DOR BioPharma Announces Publication Of OrBec(R) Clinical Pulmonary...
The investigators, led by Dr. Jason Chien, reviewed data from two previous randomized, double-blind, placebo-controlled Phase 2 and 3 clinical trials evaluating orBec , for the treatment of acute GI GVHD.
FDA Grants Orphan Drug Designation For EUR-1073 - Ulcerative Colitis For Pediatric Patients
Main Category: GastroIntestinal / Gastroenterology Also Included In: Pediatrics / Children's Health ; Regulatory Affairs / Drug Approvals Article Date: 19 Mar 2009 - 5:00 PDT Eurand N.V. , a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, ...
Study Demonstrates That QVAR is More Likely to Achieve Successful...
Study Demonstrates That QVARA is More Likely to Achieve Successful Asthma Control with Less Exacerbations © Business Wire 2009 2009-03-17 14:46:04 - Teva Pharmaceutical Industries Ltd.
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
EWING, N.J., March 13, 2009 /PRNewswire-FirstCall/ DOR BioPharma, Inc. announced today that it has appointed Brian L. Hamilton, MD, PhD, as Senior Vice President and Chief Medical Officer.
FDA Grants Eurand Orphan Drug Designation for EUR-1073
Mar 10, 2009 -- Eurand N.V., a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced that the ...
DOR BioPharma Obtains Fast Track Designation For DOR201 In The...
DOR BioPharma, Inc. announced that its program for the development of DOR201 for the prevention of acute radiation enteritis has received "Fast Track" designation from the U.S. Food and Drug Administration .
Recession is good for your health? Here's a second opinion
It was the third time in a week that I'd seen my patient, a 12-year-old girl with asthma.